Drugs that contain Revefenacin

1. Drug name - YUPELRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(2 years from now)

US7288657 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Dec, 2025

(3 years from now)

US10550081 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US9765028 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(7 years from now)

US8541451 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Aug, 2031

(8 years from now)

CN1930125A MYLAN IRELAND LTD Biphenyl Compounds Useful As Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

CN1930125B MYLAN IRELAND LTD Biphenyl Compounds Useful As Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

CN102470130B MYLAN IRELAND LTD Biphenyl Compound Is Crystalline Free Base Form
Jul, 2030

(7 years from now)

CN102470130A MYLAN IRELAND LTD Crystalline Freebase Forms Of A Biphenyl Compound
Jul, 2030

(7 years from now)

IN249707B MYLAN IRELAND LTD A Biphenyl Compound Of Formula (I)
Mar, 2025

(2 years from now)

IN200604657P1 MYLAN IRELAND LTD Biphenyl Compounds Useful As Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

EP1930323A1 MYLAN IRELAND LTD Biphenyl Compounds Useful In The Synthesis Of Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

EP1723114B1 MYLAN IRELAND LTD Biphenyl Compounds Useful As Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

EP1723114A1 MYLAN IRELAND LTD Biphenyl Compounds Useful As Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

EP1930323B1 MYLAN IRELAND LTD Biphenyl Compounds Useful In The Synthesis Of Muscarinic Receptor Antagonists
Mar, 2025

(2 years from now)

EP2453894B1 MYLAN IRELAND LTD Crystalline Freebase Form Of A Biphenyl Compound
Jul, 2030

(7 years from now)

EP2453894A1 MYLAN IRELAND LTD Crystalline Freebase Form Of A Biphenyl Compound
Jul, 2030

(7 years from now)

EP2987490A1 MYLAN IRELAND LTD Crystalline Freebase Forms Of A Biphenyl Compound
Jul, 2030

(7 years from now)

EP2987490B1 MYLAN IRELAND LTD Crystalline Freebase Forms Of A Biphenyl Compound
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists Mar, 2025

(2 years from now)

US11008289 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound Jul, 2030

(7 years from now)

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
175MCG/3ML SOLUTION;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.